The US Food and Drug Administration (FDA) and drugmaker Pharmacia are advising doctors that the firm’s COX-2 inhibitor valdecoxib (Bextra) has been associated with serious allergic reactions and should not be prescribed to patients allergic to sulfa.
In a notice issued on Friday, the FDA said it has received post-marketing reports regarding various allergic events, including skin and anaphylactoid reactions. Although the events were rare, some patients required hospitalization, the FDA added.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!